TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) Stock
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
About TaiGen Biopharmaceuticals Holdings Limited
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) stock trades at $8.94 with a market capitalization of $6.36B. The stock is valued at a price-to-earnings (P/E) ratio of 42.57, price-to-book of 6.23, price-to-sales of 24.81. Over the past 52 weeks the stock has ranged between $7.73 and $16.40, and currently trades 45.5% below its 52-week high.
On profitability, TaiGen Biopharmaceuticals Holdings Limited generates a return on equity (ROE) of 15.55%, above the typical market range of roughly 12-15%, an operating margin of -353.49%, a net profit margin of 60.49%.
Official website: www.taigenbiotech.com.tw
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) — frequently asked questions
What is TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) stock price today?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) is currently trading at $8.94, up 0.79% today.
What is 4157.TWO P/E ratio?
TaiGen Biopharmaceuticals Holdings Limited's P/E ratio is 42.57. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.
What is 4157.TWO return on equity (ROE)?
TaiGen Biopharmaceuticals Holdings Limited's return on equity (ROE) is 15.55%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.
What is TaiGen Biopharmaceuticals Holdings Limited's market cap?
TaiGen Biopharmaceuticals Holdings Limited has a market capitalization of $6.36B.
Does 4157.TWO pay a dividend?
TaiGen Biopharmaceuticals Holdings Limited is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 4157.TWO carry?
TaiGen Biopharmaceuticals Holdings Limited has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 4157.TWO's profit margin?
TaiGen Biopharmaceuticals Holdings Limited reports a net profit margin of 60.49% — the share of revenue left after every cost, including tax and interest.
What sector is 4157.TWO in?
TaiGen Biopharmaceuticals Holdings Limited is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 4157.TWO listed on?
TaiGen Biopharmaceuticals Holdings Limited trades on TWO under the ticker 4157.TWO.
What is 4157.TWO's 52-week range?
Over the last year TaiGen Biopharmaceuticals Holdings Limited has traded between $7.73 and $16.40.
Related Healthcare Stocks
Popular Stocks
Screens 4157.TWO currently matches
On the figures above, TaiGen Biopharmaceuticals Holdings Limited passes the filters for 12 of our ready-made screens, among them Low Debt Stocks, High Profit Margin Stocks, Stocks Under $10. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.